RiteMED Simvastatin Adverse Reactions

Increased serum creatine kinase concentrations of at least 3 times the upper limit of normal on ≥1 occasions occurred in approximately 5% of patients receiving simvastatin in clinical trials.
Rhabdomyolysis with acute renal failure secondary to myoglobinuria has occurred rarely with simvastatin and has required drug discontinuance.
Simvastatin was extremely well tolerated in controlled clinical trials. Only 1.4% of subjects were discontinued from therapy due to the adverse effects of simvastatin. Adverse reactions tend to be transient and mild. Constipation (2.3%), dyspepsia (1.1%) and flatulence (1.9%) were the only adverse reactions reported at a higher incidence than placebo.
The following adverse reactions were reported in >1% of patients receiving simvastatin during clinical trials: Pain, asthenia, diarrhea, nausea/vomiting and headache.